Arvinas, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARVN Nasdaq 2830 www.arvinas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arvinas, Inc.

Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation - Oct 27th, 2026 2:01 pm
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - Oct 27th, 2026 5:00 am
Could You Have Seen The Run In Kymera Stock Coming? - Oct 26th, 2026 3:34 pm
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? - Oct 19th, 2026 7:08 am
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease - Oct 16th, 2026 8:21 am
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome - Oct 16th, 2026 8:19 am
Reasons Why Investors Should Consider Betting on Arvinas Stock - Oct 13th, 2026 8:27 am
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Oct 13th, 2026 7:47 am
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Oct 13th, 2026 7:41 am
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease - Oct 7th, 2026 5:00 am
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® - Oct 1st, 2026 2:01 pm
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 29th, 2026 2:01 pm
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate - Sep 28th, 2026 5:00 am
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains? - Sep 18th, 2026 10:31 am
AdvanCell Appoints Sean Cassidy as Chief Financial Officer - Sep 15th, 2026 6:00 am
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod - Sep 9th, 2026 12:22 am
Arvinas to Participate in Upcoming Investor Conferences - Sep 3rd, 2026 2:01 pm
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - Sep 3rd, 2026 9:50 am